GLP-1 drugs work for weight loss, study finds

Ozempic 3.0? This drug causes the greatest weight loss — by far
Ozempic 3.0? Retatrutide — an experimental drug nicknamed “triple G” — could be your best shot at a slimmer waistline when it becomes available to the public, a Monday study found. Obese adults who took the weekly injection lost up to 22% of their starting weight after 11 months — compared to just 14% over 15 months for semaglutide,
Could Trump Make A Big Weight Loss Drug Deal?
Trump could keep Biden’s commitment to have Medicare pay for weight loss drugs such as Ozempic and Wegovy. But would drugmakers agree to reduce their prices right away?
How do GLP-1 drugs work for weight loss?
Dr. Mehmet Furkan Burak said people who have lost weight and then gained it again can feel guilt or shame and blame themselves for it.
Ozempic: A Diabetes Drug Driving Weight Loss? – What You Need to Know
"Because most people with obesity have elevated insulin levels, they develop insulin resistance, which contributes to weight gain. Semaglutide (or Ozempic) helps lower the levels of this fat-storing hormone, making it easier for the body to burn fat and lose weight," said Dr. Owens.
Some GLP-1s Achieve More Weight Loss Than Others: Study
We found that, of the 12 GLP-1 (drugs) identified by our search, the greatest mean body weight reduction was reported in randomized controlled trials of retatrutide, tirzepatid
GLP-1s cut surgery complication risk in some patients: Study
Glucagon-like peptide-1 receptor agonist drugs may reduce the risk of surgical complications in diabetic patients, according to a large new study. The study showed diabetic patients taking GLP-1 drugs,
GLP-1 RAs Efficacious for Weight Loss in Overweight, Obesity Without Diabetes
For adults with overweight or obesity without diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are efficacious for weight loss, according to a review published online Jan. 7 in the Annals of Internal Medicine.
Health Matters: GLP-1 drugs work for weight loss, study finds
McGill University researchers say their study has found GLP-1 drugs are safe and effective for treating obesity and overweight adults without diabetes. The authors say the findings support using the medication to treat those who are overweight and obese among otherwise healthy patients.
Weight-loss drugs like Ozempic may be up for Medicare price negotiations — will Trump support it?
Medicare’s drug pricing negotiations — the first of their kind in the United States, passed under President Joe Biden — face ...
Polls On Weight Loss And Will Power
Polls provide a useful window into understanding how Americans view their own weight and the recent availability of drugs ...
New Scientist10d
Ozempic and Wegovy have heart health benefits beyond just weight loss
A study in pigs has shown that the active ingredient in Ozempic and Wegovy directly boosts heart health, in addition to the ...
Ozempic ‘microdosing’ is the new weight-loss trend: Should you try it?
A new trend gaining popularity among people trying to lose weight is microdosing the diabetes medication Ozempic. Experts ...
Ozempic and Similar Drugs May Offer Health Benefits Beyond Weight Loss, Including Reduced Alcohol Cravings
Ozempic, Wegovy and Mounjaro, all GLP-1 anti-obesity medications, may offer health benefits beyond weight loss. Studies show ...
UK obesity rates may start falling this year thanks to weight loss jabs
Obesity levels in the UK may have peaked and could start dropping ‘significantly’ in 2025 due to weight loss jabs, according ...
FierceBiotech2d
Metsera links GLP-1 drug to 11% weight loss after 12 weeks, teeing up trial of monthly dosing
Metsera has linked its GLP-1 drug candidate to weight loss of up to 11.3% after 12 weeks, encouraging the biotech to use some ...
PBS6d
As weight loss drug demand soars, physician outlines effectiveness and potential downsides
For weight loss drugs like Ozempic and Wegovy, 2024 was a big year. More patients are relying on them to manage their weight, treat diabetes, or prevent heart attacks and strokes. And while they are ...